Grant and Funding Programs Offered by Pacific Parkinson’s Research Institute (PPRI)

Pacific Parkinson’s Research Institute (PPRI) is a Canadian charitable organization created in 1991 by the Hon. John Nichol to accelerate progress towards a world without Parkinson’s disease. The institute has a clearly defined mandate: to provide financial support for world‑class research conducted at the University of British Columbia’s Pacific Parkinson’s Research Centre (PPRC), the only medical clinic in British Columbia dedicated exclusively to the diagnosis and management of Parkinson’s. By concentrating its resources on this Centre of Excellence, PPRI helps sustain a critical mass of investigators and infrastructure focused on Parkinson’s research.

PPRI’s funding covers the full‑time employment and research programs of leading clinician‑scientists at PPRC, including the centre’s director, Dr. Silke Appel‑Cresswell. The institute has also endowed major academic positions such as the Marg Meikle Professorship in Parkinson’s Research and supports the John L. Nichol Chair in Parkinson’s Research. These long‑term commitments ensure stable research capacity in neurology, neuroimaging and related disciplines at UBC.

PPRI primarily operates as a discretionary research funder rather than through open public competitions. It channels donations and legacy gifts into strategic initiatives at PPRC, focusing on cutting‑edge and sometimes high‑risk pilot projects that may be difficult to fund through traditional grant agencies. The website highlights a diverse portfolio of current and past projects, including studies on multimodal neuromodulation, low‑intensity focused ultrasound, microbiome and gut–brain interactions, exercise and brain energetics, non‑invasive brain stimulation, sleep disruption, 3D bioprinting of neural tissue, data platforms such as NeuroSeq, and large repositories like the Bjorn Moller Research Repository.

In addition to project grants, PPRI supports trainee development through mechanisms such as the James A. Moore Fellowship, which helps identify and invest in high‑potential student researchers working with the PPRC team. It also collaborates with programs like Health Research BC’s trainee initiatives, connecting its funded researchers to the broader health research ecosystem in British Columbia.

PPRI emphasizes a close partnership model with its donor community. Each year, it organizes an Annual Scientific Review where senior PPRC researchers present on PPRI‑supported projects, share interim findings and discuss future research directions. Donors are invited to meet scientists, ask questions and receive written updates on funded work. This approach provides a high degree of visibility into how contributions are allocated and what impact they have on clinical practice and scientific knowledge.

Governance is provided by a volunteer Board of Directors, many of whom have direct personal experience with Parkinson’s disease, either themselves or through close family members. This lived experience informs funding priorities and reinforces the institute’s focus on research with clear potential to improve patients’ quality of life, from innovative imaging and neuromodulation techniques to personalized care models and remote monitoring technologies.

While PPRI does not run broad open calls for proposals, its funding significantly benefits multiple groups: neurologists and clinician‑scientists at UBC, early‑career researchers and trainees, and ultimately people living with Parkinson’s throughout British Columbia and beyond. By underwiting salaries, fellowships, infrastructure and exploratory projects, the institute helps maintain Canada’s largest peer‑reviewed Parkinson’s research program and contributes to international advances in understanding disease mechanisms and therapies.

Through targeted, donor‑driven financial support, Pacific Parkinson’s Research Institute plays a specialized yet influential role in the Parkinson’s research funding landscape, complementing public agencies and national foundations with flexible, high‑impact research investment.